Xintela prepares for oncology spinout

Xintela AB (publ) announces today that the company has decided to prepare for a possible spin-out of its oncology business into a separate company to be distributed to Xintelas existing shareholders through a stock dividend and listed on a suitable stock market during 2018. Since 2014, Xintela’s cancer project focusing on the aggressive brain tumor […]

Xintela licenses human antibody technology for cancer therapy

Xintela AB (publ) today announced the company has licensed antibody technology for the development of human antibodies in diagnostics and therapy. The antibodies, directed to Xintela’s markers integrin 101 och integrin 111, are already adapted for human use. This means that Xintela saves both time and money and that Xintela’s cancer products can be tested […]

Xintela to collaborate with Japanese CellSeed Inc.

Xintela AB (publ) announces today that the company has signed a collaboration agreement with the leading Japanese cell therapy company, CellSeed, for its development of a cell therapy product for the treatment of cartilage damage in the knee joint. “It is very exciting that we have established a collaboration in Japan which, due to a […]

Xintela raises 17 million SEK in debt and equity

Xintela AB (publ) announces a directed share issue of approximately 10 million SEK and borrowing of 7 million SEK to strengthen its working capital for investment in Xintela’s development programs. The Board of Xintela, under the authorization adopted at the AGM on 18 May 2017, today decided to issue a total of 3,205,129 new shares, […]

Keld Søndergaard leaves Xintela’s Board of Directors

Xintela AB (publ) announces that Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons. Xintela’s larger shareholders, acting as an informal nomination committee, will consider potential replacement candidates to propose to the next Annual General Meeting. Keld Søndergaard was elected as a new member of the Board at the Annual General […]

Xintela building own GMP-facility for stem cell production

Xintela AB (publ) announces the company has decided to bring forward the construction of its own facility for production of equine and human stem cell-based ATMPs (Advanced Therapy Medicinal Products) at Medicon Village, Lund. Initially, stem cells will be produced for clinical studies in horses. After careful evaluation of available options, Xintela has decided to […]

Xintela recruits Liselotte Theorell as Director Product Development and Quality Management

Xintela AB (publ) announces that the company has recruited Liselotte Theorell as Director Product Development and Quality Management. The recruitment is an important step towards the production of stem cells under GMP (Good Manufacturing Practice) for upcoming clinical studies. “Liselotte is one of few persons in Sweden who possess such extensive competence in quality management […]